Features Screener Stocks Charts
Sign In Sign Up

AstraZenca Pharma India Ltd. Cash Flow Statement

NSE:ASTRAZEN | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.42x

ASTRAZEN's operating cash flow was significantly below net income in FY 2025, suggesting earnings include substantial non-cash items.

Free Cash Flow

₹636.10M

ASTRAZEN's free cash flow was ₹636.10M in FY 2025, up 271.8% from FY 2024.

Dividend Coverage

1.1x

ASTRAZEN's free cash flow covered dividends 1.1x in FY 2025 but leaves limited surplus.

CapEx Intensity

2.7%

Capital expenditure was 2.7% of operating cash flow in FY 2025 for ASTRAZEN, indicating a capital-light business.

2-year ASTRAZEN cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 2.20B 1.56B
Cash flow Operating Activities 278.70M 653.60M
Investments in PPE -107.60M -17.50M
Cash flow Investing Activities 217.40M 308.00M
Dividend Paid -400.00M -600.00M
Cash flow Financing Activities -443.80M -655.90M
Cash at beginning of period 5.00B 5.06B
Cash at end of period 5.06B 5.36B
Free Cash Flow 171.10M 636.10M

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025